



For Immediate Release

**RedPath Integrated Pathology, Inc. to Present at Rodman & Renshaw Global
Investment Conference in New York**

*Molecular diagnostics leader to provide perspectives on emerging in-vitro diagnostic
applications*

Pittsburgh, PA, August 17, 2009 – [RedPath Integrated Pathology](#), Inc., a molecular diagnostics company dedicated to the effective diagnosis and treatment of cancer, today announced that [Mark D. Myslinski](#), RedPath's president and chief executive officer, will share his perspectives on the rapidly expanding applications of molecular diagnostics at the Rodman and Renshaw 11th Annual Healthcare Conference. The conference will be held in New York City, September 9-11, 2009.

The three-day conference attracts an international audience of healthcare industry executives, private equity firms, investors and venture capitalists. Conference sessions will provide insight into emerging areas of molecular diagnostics, oncology, stem cells and gene therapy.

Mr. Myslinski will be presenting at 3:40 p.m. on September 10th in the Fahnestock Salon (5th Floor) of the New York Palace Hotel. He will offer attendees insight into RedPath's unique application of molecular diagnostics, *PathFinderTG*[®], and how it provides detailed, actionable clinical information to help physicians previously challenged by indeterminate or indefinite diagnostic tests.

"We are looking forward to sharing RedPath's unique diagnostics offering at the upcoming Rodman and Renshaw Healthcare Conference," said Mr. Myslinski. "Our methodologies have shown the ability to improve the lives of people with cancer by applying novel diagnostic tools to solve clinical patient management dilemmas. This

meeting will provide a forum for RedPath Integrated Pathology, Inc. to share the company's results and plans with a sophisticated audience of investors knowledgeable about healthcare."

About RedPath Integrated Pathology Inc.

RedPath Integrated Pathology, Inc. is a genomics-based molecular diagnostics company that provides complex cancer diagnostic testing for pathologists, oncologists and clinicians. RedPath's patented molecular-based analysis, *PathFinderTG*[®], integrates with routine pathology review of fixed slides, cytology and fluid specimens to render an earlier and more definitive diagnosis, improving patient outcomes and reducing healthcare costs. For more information about RedPath, please visit www.redpathip.com.

Contact:

Mark D. Myslinski
President and CEO
RedPath Integrated Pathology
412-224-6100
mdm@redpathip.com